230 likes | 334 Views
Restoring Sight. Treatment Options. Currently available: Vitamin A Has not shown consistent benefits in clinical evaluation. In clinical trials: Retinal Prosthesis Vision limited to few pixels. Optogenetic Treatment for RP. 1. Algae. 2. Gene therapy injection. Light-sensitive genes
E N D
Treatment Options Currently available: Vitamin A Has not shown consistent benefits in clinical evaluation In clinical trials: Retinal Prosthesis Vision limited to few pixels
Optogenetic Treatment for RP 1. Algae 2. Gene therapy injection Light-sensitive genes are extracted Genes are added to patient’s DNA 3. Light mediation Light is shone directly into eyes Re-grow rods + cones in retina 5. A Better Life
Patient Population Size Pricing Benchmarks Target market size: 10,000 x$60,000 = $600 Million
Bottom Up Market Size Analysis US target market size: $540 million
Revenue Model Therapeutic Package $$$ Patient Payer Purchaser User
Partners & Allies Intellectual Property Grants $$$ IP $$$ Venture Capital Equity Clinical Trials $$$ Core Competency: Research + Development $$$ Data, FDA Approval $$$ Manufacturers Gene Therapy Serum Optical Device
Timeline Pre-Animal Research Safety & Tolerability Research Animal Research Preclinical Research Phase I Phase II Phase III Clinical Trials Market launch year 3 year 1 year 2 today year 4 year 5
Major Risks Technology Regulatory Regulatory Market Market Market Clinical Development Pre-Clinical
Major Expenses Patent and Licensing Costs 5 patents * ~40K = ~$200K Development Hiring the Initial Team 3 yrs * (CEO+CSO) = ~1MM 3 yrs * (key hires) = ~1.5MM Trial Contractors $400K (pre-clinical) + $50K (animal) Pre-clinical Research Lab Upkeep 3 yrs * $250K = $750K Clinical Trials $4000/patient * 200 = $800K Clinical Sales / Marketing 50 reps * $50K = 2.5MM
Initial Core Team Founders Scientific Advisory Board
Conclusion Mission: Restoring vision to RP patients who currently lack a solution Market: US market $700-800M World market $2.1-2.4B Risk: Significant technical and regulatory risk; partially mitigated by risk benefit profile for RP Future: Platform technology with wide IP coverage, has spectrum of promising therapeutic applications
New patient market size US target market size: $14 million